Americas Healthcare Generic Pharmaceuticals

The Supreme Court's ruling in favor of Hikma regarding Amarin's Vascepa patents clarifies the 'skinny label' pathway for generic manufacturers. This decision reduces legal risks for the generic sector and is viewed as a positive development for companies like AMRX, TEVA, and VTRS.

Key Takeaways

• 1.The US Supreme Court ruled unanimously in favor of Hikma regarding its generic 'skinny label' product, finding no induced infringement of Amarin's patents.
• 2.The ruling provides greater clarity and confidence for generic manufacturers using the 'skinny label' (Section viii) pathway.

Table of Contents

• Background
• Valuation and Risks
• Disclosure Appendix